Sitagliptin in the treatment of type 2 diabetes: a meta‐analysis

@article{Zhan2012SitagliptinIT,
  title={Sitagliptin in the treatment of type 2 diabetes: a meta‐analysis},
  author={Mei Zhan and Ting Xu and Fengbo Wu and Yao Tang},
  journal={Journal of Evidence‐Based Medicine},
  year={2012},
  volume={5}
}
Objective: To evaluate the benefits and harms of sitagliptin in people with type 2 diabetes mellitus. 

A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone

Sitagliptin was generally well tolerated and provided statistically superior and clinically meaningful improvements in gly glucose control after 24 weeks of treatment compared to placebo when added to treatment of patients with inadequate glycemic control on acarbose monotherapy.

DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews

The methodological quality of SRs of DPP4-I for type 2 diabetes mellitus is not high and there are common areas for improvement, and the quality of evidence level is moderate and more high quality evidence is needed.

Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up

A clinical meaningful improvement in glycemic control was seen when DPP-4 inhibitors were added to other anti-diabetic medications in patients with T2DM regardless of age, duration of T2 DM, type of combination treatment regimen.

Inhibidores de dipeptidil dipeptidasa-IV: de la teoría a la práctica

This review of dipeptidyl peptidase-IV inhibitors seeks to encourage the rational use of these drugs in daily practice; this group is a new therapeutic option in monotherapy or combination therapy

Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice

Combination therapy with Pro 3 (GIP) and sitagliptin improved metabolic abnormalities in diabetic mice and significantly greater reductions of blood glucose and triglycerides than either monotherapy.

Assessment of β-Cell Function

These range from basal pharmacokinetic measures, e.g. measurement of fasting serum insulin concentration, to dynamic tests that measure insulin responses to glucose ± non-glucose stimuli, which have value in the early-phase development of new drugs for diabetes treatment.

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial

The overall HbA1c-lowering effect and incidence of AE were similar for sitagli leptin, vildagliptin and saxaglipt in Chinese adults with newly diagnosed diabetes.

Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment

Mitiglinide or combination treatment resulted in lower glycemic variability and postprandial glucose excursion than sitagliptin alone; however, the results of this single-day pharmacodynamics study cannot be generalized to a clinical setting.

Effect of a low dose whey/guar preload on glycemic control in people with type 2 diabetes-a randomised controlled trial

An 80 kcal whey protein/fibre preload can lower average glucose over 3 hours by 0.8 mmol/L and if used long term before at least two carbohydrate-rich meals/day this preload could lower HbA1c by up to 1%.

References

SHOWING 1-10 OF 28 REFERENCES

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

Aim: To compare the efficacy and safety of monotherapy with sitagliptin and metformin in treatment‐naïve patients with type 2 diabetes.

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Objective: To evaluate the efficacy and tolerability of sitagliptin when added to insulin therapy alone or in combination with metformin in patients with type 2 diabetes.

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes *

The addition of sitagliptin to ongoing metformin therapy in patients with type 2 diabetes who were inadequately controlled on met formin monotherapy is assessed.

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

The primary aim is to compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and inadequate glycaemic control on metformin monotherapy.

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

To assess the efficacy and safety of a 24‐week treatment with sitagliptin, a highly selective once‐daily oral dipeptidyl peptidase‐4 (DPP‐4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control while on glimepiride alone or in combination with metformin.

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Sitagliptin significantly improved glycaemia control and was well tolerated in patients with type 2 diabetes mellitus who had inadequate glycaemic control on exercise and diet.

Treatment options for type 2 diabetes: introducing the incretin-based therapies

diabetes mellitus (T2DM), glycaemic control is often difficult to maintain and current treatments can produce adverse effects. The incretin-based therapies - dipeptidyl peptidase-4 inhibitors and

Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Review of the literature to date implies sitagliptin may be effective as monotherapy in type 2 diabetes, and existing evidence supports the use of sitgliptin as adjunct therapy to sulfonylureas and metformin.